Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care
Open Access
- 28 September 2024
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (1) , 1-11
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 54 references indexed in Scilit:
- SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trialsBreast Cancer Research and Treatment, 2024
- Incidence, risk factors, and management of alpelisib‐associated hyperglycemia in metastatic breast cancerCancer, 2023
- Sodium-glucose cotransporter-2 inhibitors for hypergycemia in phosphoinositide 3-kinase pathway inhibitionBreast Cancer Research and Treatment, 2023
- Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancerBreast Cancer Research and Treatment, 2022
- Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatmentCancer Medicine, 2022
- Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancerBreast Cancer Research and Treatment, 2022
- Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerAnnals of Oncology, 2020
- Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancerBreast Cancer Research and Treatment, 2020
- The prognostic value of PI3K mutational status in breast cancer: A meta‐analysisJournal of Cellular Biochemistry, 2018
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisAdvances in Therapy, 2013